Epidemiology of Renal Cell Carcinoma.
Epidemiology
Incidence
Kidney cancer
Mortality
Prevalence
Renal cancer
Journal
European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
16
06
2018
accepted:
28
08
2018
pubmed:
24
9
2018
medline:
7
6
2019
entrez:
24
9
2018
Statut:
ppublish
Résumé
Despite the improvement in renal cell carcinoma (RCC) diagnosis and management observed during the last 2 decades, RCC remains one of the most lethal urological malignancies. With the expansion of routine imaging for many disorders, an increasing number of patients who harbour RCC are identified incidentally. To summarise and compare RCC incidence and mortality rates, analyse the magnitude of risk factors, and interpret these epidemiological observations in the context of screening and disease management. The primary objective of the current review was to retrieve and describe worldwide RCC incidence/mortality rates. Secondly, a narrative literature review about the magnitude of the known risk factors was performed. Finally, data retrieved from the first two steps were elaborated to define the clinical implications for RCC screening. RCC incidence and mortality significantly differ among individual countries and world regions. Potential RCC risk factors include behavioural and environmental factors, comorbidities, and analgesics. Smoking, obesity, hypertension, and chronic kidney disease represent established risk factors. Other factors have been associated with an increased RCC risk, although selection biases may be present and controversial results have been reported. Incidence of RCC varies worldwide. Within the several RCC risk factors identified, smoking, obesity, and hypertension are most strongly associated with RCC. In individuals at a higher risk of RCC, the cost effectiveness of a screening programme needs to be assessed on a country-specific level due to geographic heterogeneity in incidence and mortality rates, costs, and management implications. Owing to the low rates of RCC, implementation of accurate biomarkers appears to be mandatory. The probability of harbouring kidney cancer is higher in developed countries and among smokers, obese individuals, and individuals with hypertension.
Identifiants
pubmed: 30243799
pii: S0302-2838(18)30633-X
doi: 10.1016/j.eururo.2018.08.036
pmc: PMC8397918
mid: NIHMS1730066
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
74-84Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Références
Br J Cancer. 2001 Sep 28;85(7):984-90
pubmed: 11592770
Ann Oncol. 2008 May;19(5):1003-8
pubmed: 18187482
BMJ Open. 2018 Jan 24;8(1):e018859
pubmed: 29371278
Environ Toxicol Pharmacol. 2015 Nov;40(3):828-46
pubmed: 26476885
J Med Screen. 2017 Jun;24(2):104-109
pubmed: 28482765
Eur Urol. 2016 Sep;70(3):458-66
pubmed: 26149669
Urol Oncol. 2016 Apr;34(4):167.e9-16
pubmed: 26602092
J Nephrol. 2017 Dec;30(6):851-857
pubmed: 28317077
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Br J Cancer. 2013 Mar 5;108(4):798-811
pubmed: 23412105
Curr Opin Urol. 2017 Sep;27(5):409-414
pubmed: 28650865
Int J Cancer. 2013 Sep 15;133(6):1452-8
pubmed: 23463659
Cancer Causes Control. 2002 Apr;13(3):287-93
pubmed: 12020111
Int J Cancer. 2014 Jan 15;134(2):384-96
pubmed: 23400756
Int J Cancer. 2006 Jun 15;118(12):3133-9
pubmed: 16425278
Sci Rep. 2015 Dec 11;5:17976
pubmed: 26656678
J Cancer. 2017 Jan 1;8(1):9-18
pubmed: 28123593
J Hypertens. 2017 Jul;35(7):1333-1344
pubmed: 28157813
J Am Soc Nephrol. 2014 Oct;25(10):2327-34
pubmed: 24876115
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Oncotarget. 2015 May 30;6(15):13347-58
pubmed: 25965820
QJM. 2015 Mar;108(3):205-12
pubmed: 25208892
Nutr Cancer. 2013;65(5):668-76
pubmed: 23859034
Int J Cancer. 2015 Jul 1;137(1):238-42
pubmed: 25431248
BJU Int. 2008 Apr;101(8):949-58
pubmed: 18241251
Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):358-364
pubmed: 29424894
Int J Cancer. 2015 Oct 15;137(8):1953-66
pubmed: 25866035
Maturitas. 2007 Oct 20;58(2):156-63
pubmed: 17822863
World J Urol. 2018 Sep;36(9):1341-1353
pubmed: 29610964
Br J Cancer. 2002 May 6;86(9):1425-9
pubmed: 11986775
PLoS One. 2013 Oct 28;8(10):e75732
pubmed: 24204579
Diabetes Care. 2011 Jul;34(7):1552-6
pubmed: 21602426
Br J Cancer. 2011 Feb 1;104(3):537-41
pubmed: 21245859
Eur Urol Focus. 2015 Aug;1(1):52-53
pubmed: 28723356
Nat Rev Urol. 2010 May;7(5):245-57
pubmed: 20448658
JAMA Intern Med. 2018 Feb 1;178(2):221-227
pubmed: 29279887
J Urol. 2013 Nov;190(5):1657-61
pubmed: 23665301
J Natl Cancer Inst. 2013 Sep 18;105(18):1355-64
pubmed: 23990666
Cancer Res. 2010 Aug 15;70(16):6527-36
pubmed: 20663906
Am J Epidemiol. 2009 May 15;169(10):1243-50
pubmed: 19329527
Lancet Diabetes Endocrinol. 2018 Jun;6(6):e6-e15
pubmed: 29803268
Br J Cancer. 2007 Mar 12;96(5):845-9
pubmed: 17311018
Dig Dis Sci. 2015 Jun;60(6):1820-4
pubmed: 25592719
Mayo Clin Proc. 2015 Jan;90(1):35-42
pubmed: 25572193
Anticancer Res. 2018 Jul;38(7):4123-4130
pubmed: 29970539
Arch Intern Med. 2011 Sep 12;171(16):1487-93
pubmed: 21911634
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
Cancer Causes Control. 2017 Jul;28(7):801-807
pubmed: 28484923
Med Hypotheses. 2006;66(4):732-5
pubmed: 16364563
Br J Clin Pharmacol. 2014 Mar;77(3):458-65
pubmed: 23879311
J Urol. 2014 Jun;191(6):1665-70
pubmed: 24423441